Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Veltassa found to lower blood pressure, aldosterone levels
August 2016
SHARING OPTIONS:

REDWOOD CITY, Calif.—Relypsa Inc. recently shared results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa (patiromer) for oral suspension. The study sought to assess Veltassa's performance in patients with hyperkalemia and chronic kidney disease (CKD) who were taking renin angiotensin aldosterone system inhibitors, and this analysis found that study participants saw significant decreases in systolic and diastolic blood pressure and reduced levels of aldosterone, which plays a role in the regulation of blood pressure and potassium levels.
 
“This analysis suggests that patiromer’s potassium-lowering effects may be associated with reductions in blood pressure and aldosterone production. These findings could be important for people with CKD and are worth evaluating further,” commented Dr. Matthew R. Weir, lead investigator of the OPAL-HK trial and professor and director of the Division of Nephrology at the University of Maryland School of Medicine in Baltimore.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.